Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03420781 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
NCT03420781 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 467 participants.
The verdict
NCT03420781, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
Study Summary
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.
Interventions
- DRUG Placebo
- DRUG Relamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03420781
The ClinicalTrials.gov registry entry for NCT03420781 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03420781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03420781 about?
NCT03420781 is a clinical study titled "A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03". A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.
What is the current status of trial NCT03420781?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2018-01-24. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03420781?
The interventions under investigation include: Placebo (DRUG), Relamorelin (DRUG).
Who is sponsoring clinical trial NCT03420781?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.